$7.12
+0.13 (+1.86%)
Performance
1D
—
1W
—
1M
—
3M
—
6M
-62.53%
1Y
-62.53%
YTD
-62.53%
Open$6.96
Previous Close$6.99
Day High$7.28
Day Low$6.75
52W High$24.37
52W Low$5.50
Volume—
Avg Volume79.2K
Market Cap4.41B
P/E Ratio—
EPS$-1.17
SectorN/A
Technical Indicators
Full analysis →
RSI (14)
72.7
Overbought
Analyst Ratings
Strong Buy
7 analysts
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 897.79M | 924.30M | 800.01M |
| Net Income | 130.26M | 123.87M | 128.43M |
| Profit Margin | 14.5% | 13.4% | 16.1% |
| EBITDA | 262.26M | 279.12M | 215.46M |
| Free Cash Flow | 117.43M | 106.34M | 120.15M |
| Rev Growth | +21.7% | -6.1% | -8.9% |
| Debt/Equity | 0.23 | 0.23 | 0.24 |
N/A Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| PICS | Pics Nv | $10.50 | -4.46% | 6.0 | 1.36B |
| DMII | Drugs Made In America Acquis | $10.09 | -0.10% | 75.0 | 643.37M |
| CCCX | Churchill Capital Corp X-A | $10.08 | -5.62% | — | 2.32B |
| BEAG | Bold Eagle Acquisition Cor-A | $10.65 | +0.09% | 35.1 | 333.22M |
| CEPF | Cantor Equity Partners-Cl A | $10.36 | +0.19% | 57.6 | 593.22M |
| BCSS | Bain Capital Gss Inv- A | $10.21 | +0.00% | 71.9 | 596.26M |